

# Index

## A

Ab initio/de novo, 255, 256  
Ab initio method, 201, 202  
ABO blood groups, 10  
Absence of heterozygosity (AOH), 63  
Adsorption, distribution, metabolism and excretion (ADME)  
  antibiotics and herbal-based leads, 262  
  computational tools and web servers, 258  
  herbal sources, 262  
  hERG gene, 262  
  lead molecules, 258–260  
  mutagenicity, 258  
  pharmacophore-based virtual screening, 262  
  QSAR-based virtual screening, 263  
  toxicity profiles, 258, 261  
Affymetrix microarray chip technology, 12  
African Americans (Afr-Amr), 53  
American College of Medical Genetics (ACMG), 63, 65–67  
American College of Obstetrics and Gynecology (ACOG), 69  
Amikacin and kanamycin, 238  
ANNOVAR, 46  
Antimicrobial resistance (AMR), 188  
Anti-tuberculosis drugs  
  amikacin and kanamycin, 238  
  bedaquiline, 239  
  conventional therapies, 241–243  
  cycloserine, 239  
  delamanid, 239  
  ethambutol, 238  
  ethionamide, 239  
  fluoroquinolones, 239  
  isoniazid, 237  
  linezolid, 240

  pyrazinamide, 238  
  rifampicin, 238  
  streptomycin, 238

ArgA, 237

Array comparative genomic hybridization (aCGH), 63

Autoimmune diseases, 11

Autoimmune inflammatory diseases, 152, 158

## B

Bacterial infection, 218

BaseRecalibrator, 44

Bayesian model-based algorithm, 45

Bedaquiline, 239

$\beta$ -lactamases, 187

Biochemical pathways, 236

Biofilm bacteria, 137

Biofilms

  autoaggregative interactions, 137

  microbiome, 137

  microfluidic system, 139

  nutrient source, 139

  oral cavity, 138

Bioinformatics

  biomedical, 2

  GenBank and BLAST, 1 (*see also* Gene expression profile)

  high-throughput technologies, 6

  sequencing technologies

    applications, 4, 5

    biostatistics, 5

    GWAS, 5

    high-throughput, 5

    single cell genomics, 5

    DNA and RNA, 2

- Bioinformatics (*cont.*)
- HiSeq, 3
  - Illumina/Solexa, 3
  - MiSeq, 3
  - nanopore technology, 4
  - NextSeq, 3
  - NGS, 3
  - NovaSeq, 4
  - thermo fisher range, 4
  - technological breakthroughs, 1
- Biologists, 9
- Biostatisticians, 9
- Biotech companies, 32
- Blood-brain barrier (BBB), 258
- Burrows-Wheeler transformation (BWT), 43
- C**
- Caenorhabditis elegans*, 133
- Cancer precision medicine
- antibiotics, 105
  - drug development, 115
  - EGFR, 106
    - activating mutations, 108
    - carboplatin/paclitaxel, 108
    - data and analyse, 109
    - efficacy profile, 110
    - exploratory analysis, 108
    - gefitinib and erlotinib, 110
    - IPASS, 107
    - PFS, 107
    - pre-malignant and malignant tissues, 107
    - signalling pathway, 106–107
    - TRUST, 109 (*see also* First generation EGFR TKIs)
  - HER2 gene, 106
  - Herceptin, 106
  - key drivers, 105
  - molecular techniques, 106 (*see also* Non-small cell lung cancer (NSCLC))
  - NSCLC, 106
  - opportunities, 115 (*see also* Second generation EGFR TKIs)
  - strategy, 115
  - technologies and empowered, 106
  - therapeutic, 105
- Capture sandwich (CS), 156
- Cardiovascular diseases, 14
- Case-control analysis
- biological samples, 52
  - confounding factors, 52
  - hypothetical genotype data, 52
  - logistic regression model, 52, 53
- Catalyst software, 193
- Caucasian Americans (Cau-Amr), 53
- Cell-based therapy, 168
- Cellular models, 133
- Centers for Disease Control and Prevention (CDC), 236
- Chromatin immunoprecipitation sequencing (ChIP-Seq), 42
- Chromosomal microarray analysis (CMA)
- advantages, 64
  - analysis and reporting, 63, 64
  - cancer diagnosis
    - B-cell activation, 71
    - classification of neoplasms, 70
    - cytogenetics, 70
    - diverse genetic abnormalities, 71
    - embryonal tumors, 73
    - germinal center formation, 71
    - hematological malignancies, 71, 72
    - high-resolution oligonucleotide array, 73
    - hyperdiploid clone, 72
    - hyperdiploidy, 71
    - microarray testing, 71, 72
    - Oncoscan array, 72
    - pseudo-hyperdiploidy, 71
    - whole genome analysis, 73
  - conventional cytogenetics, 62
  - diagnostic tool, 62
  - Down syndrome, 62
  - limitations, 65
  - microarray technology, 62, 63
  - microchip-based testing platform, 62
  - microdeletions and microduplications, 62
  - postnatal diagnosis, 65, 67, 68
  - prenatal diagnosis, 69, 70
- Chronic lymphocytic leukemia (CLL), 72
- Clinical sequencing nomenclature (CSN), 94
- Coarse-grained molecular dynamics (CG-MD), 215
- Combined Annotation Dependent Depletion (CADD), 46
- Comparative molecular field analysis (CoMFA), 195, 196
- Comparative molecular similarity indices analysis (CoMSIA), 196
- Competitive ELISA, 156
- Complex disease, 11–14, 16
- Computational methods
- targeting bacterial infections, 206, 208, 209, 213, 219
  - toxicity, 216, 217
- Computer-aided drug designing/discovery (CADD), 189, 234
- connectivity map, 244
  - HTS, 244

- interdisciplinary field, 244
  - limitations, 244
  - MM/GBSA, 244
  - network-based approaches, 240
  - SIE, 244
  - structure-based virtual screening, natural compounds, 244
  - ConDel, 96, 98
  - Congenital heart disease (CHDs), 67
  - Copy number variants (CNVs), 42, 44, 45
  - Cycloserine, 239
  - Cystic fibrosis (CF), 30
- D**
- D-alanyl-D-alanine (DADA), 188
  - Database for Annotation, Visualization and Integrated Discovery (DAVID), 161
  - dbNSFP, 96, 98
  - dbSNV, 98
  - Deciphering Developmental disorders (DDD), 30
  - Delamanid, 239
  - Density functional theory (DFT), 212
  - Dental caries, 123
  - Dental disease
    - databases, 141, 143
    - dental caries, 123
    - EMBL, 142
    - gene mapping, 123
    - oral cancer, 125
    - periodontal disease, 125
    - saliva, 124
    - web resources, 143
  - Dental pulp stem cells (DPSCs), 129
  - Dental stem cells
    - cavity, 121
    - cell lineages, 127
    - dental diseases, 123
    - DPSCs, 129
    - equilibrium, 121
    - PASCs, 131
    - PDLSCs, 130
    - pharyngeal arch, 122
    - plaque, 121
    - SGSC, 130
    - structure, 122
    - tissue regeneration and functional restoration, 121
  - DevR, 237
  - Disease Control Rate (DCR), 109
  - Dissipative particle dynamics (DPD), 215
  - Distant regulatory elements (DiRE)
    - co-expression behaviour, 286
    - disease- and trait-associated variants, 285
    - enhancers, 284, 285
    - gene expression, 284, 285
    - gene regulation, 285
    - hormones, 284
    - hypergeometric distribution, 286
    - intergenic regions and exons, 284
    - limitations, 295
    - molecular pathology, 284
    - pharmaceutical and clinical research, 285, 286
    - promoter-distal cis-regulatory elements, 284
    - protein-coding mutations, 285
    - set of genes, 286, 288
    - transcription, 284
    - transcription factor (TF), 294
    - TRANSFAC/JASPAR, 285
    - use/advantages, 292
  - Docking studies, 174
  - Drug delivery
    - computational methods, 213, 214
  - Drug discovery
    - computational, 210
    - fast-paced drug discovery programs, 211
    - genomics and proteomics, 187
    - modern era, 187
    - protein-ligand docking, 197
    - small molecules, 191, 205
    - traditional, 189
  - Drug likelihoods
    - ADMET (*see* Adsorption, distribution, metabolism and excretion (ADME))
  - Drug-polymer interaction, 215, 216
  - Duchenne muscular dystrophy, 10
- E**
- Ensembl genome browser, 28, 101
  - Enzyme-linked immunosorbent assays (ELISA), 156
  - Epidermal growth factor receptor (EGFR), 106
  - Essential genes, 237
  - Ethambutol, 238
  - Ethionamide, 239
  - European Bioinformatics Institute (EBI), 14, 141
  - European Centre for Disease Prevention and Control (ECDC), 235
  - European Molecular Biology Laboratory (EMBL), 141
  - European Union and European Economic Area (EU/EEA), 235
  - Evolutionarily conserved regions (ECRs), 285
  - Exome Aggregation Consortium (ExAC), 97
  - Exome sequencing, 33

- Expression quantitative trait loci (eQTLs), 50, 53
- Extended spectrum  $\beta$ -lactamases (ESBLs), 187
- Extreme drug resistance (XDR)  
Mtb (*see Mycobacterium tuberculosis* (Mtb))
- F**
- First generation EGFR TKIs  
mutant and WT EGFR, 110  
toxicity issues, 111  
T790M, 112
- Fluorescence in situ hybridization (FISH)  
assays, 62
- Fluoroquinolones, 239
- Foetal stem cells, 128
- Fold recognition, 255
- Formalin-fixed paraffin-embedded (FFPE), 64, 72
- Framingham Heart study, 15
- FreeBayes, 45
- Free-energy perturbation method (FEP), 209
- Functional analysis, 169
- G**
- Gene expression profile  
biological technologies, 7  
database, 7  
GTEx, 7  
NCBI and EMBL, 7  
*Nucleic Acid Research* journal, 7  
single gene expression, 6
- Gene polymorphisms, 142
- Generalized-Born/surface area (GB/SA), 209
- Genesis Software, 162
- Genetic association studies  
bioinformatics field, 9  
blood-related diseases, 10  
DNA architecture and organization, 9  
early DNA marker development and application, 10
- Genetic diagnosis, 26
- Genetic disease, 86
- Genetic homogeneity, 14
- Genetic markers, 10, 14, 16
- Genome Analysis Toolkit (GATK), 44
- Genome-wide association studies (GWAS), 50, 285  
genetically isolated/homogeneous populations, 13–15  
human genome project, 11, 12  
microsatellite markers, 11  
national biobank and genome projects, 15–17
- Genomic annotation, 87
- Genomic variation, 86, 87, 101
- Genomics England, 35
- Genotype data analysis, 52
- Genotype Tissue Expression (GTEx), 7
- Germ line stem cells (GSCs), 168
- GFR alpha 1, 169, 174, 176
- Glioblastoma multiforme (GBM), 73
- Global Alliance for Genomic Health (GA4GH), 93
- Grand average of hydrophobicity (GRAVY), 172
- Graphical processor unit (GPU), 211
- GraphPad Prism (Version 7) software, 159
- H**
- Head and neck squamous cell carcinoma (HNSCC)  
cancers, 47  
disparity, 53  
molecular characterization and subtypes, 47, 48  
mutational landscapes, 48  
risk, 48–52  
risk factors, 47  
survival, 53
- Hidden Markov models (HMMs), 94
- High-content screening (HCS), 131  
advantages, 131  
biomedical application, 134  
genomes, 134  
HTS, 131  
oro-dental disorders, 136  
RNA-Seq and microarray, 137  
second-generation sequencing, 135  
sequencing platforms, 135
- High-throughput screening (HTS), 131, 189, 196, 244  
miniaturization, 133  
pharmaceutical companies, 131
- High-throughput technologies, 26, 32, 86  
FASTA and BLAST, 28  
genetic diagnosis, 26  
genetic diseases, 27  
genetics groups, 28
- HNSCC risk  
genetic association studies  
case-control analysis, 52  
epidemiological approaches, 50  
SNPs identification in TP53, 51  
germline genetic polymorphisms, 50  
GWAS, 50

- International HapMap project, 48
    - SNPs, 50
  - Homology modelling, 248, 255
  - Human Cytokine Magnetic 30-Plex Panel (LHC6003M), 159
  - Human Genic Bi-Allelic Sequences (HGBASE), 142
  - Human genome, 26–29
  - Human Genome program, 26
  - Human Genome Project (HGP), 27, 28, 33, 40, 134
    - application, 29
    - polygenic diseases, 29
    - rapid-sequencing technologies, 29
    - rare diseases programs, 29
    - sequence and analysis tools, 29
    - UK, 35
    - UK Biobank, 35
    - USA, 34
    - YAC, 28
  - Human genome sequence, 86
  - Human Genome Variation Society (HGVS), 94, 97, 98
  - Human papilloma virus (HPV), 47
  - Huntington disease, 27
  - Huntington disease gene mutation, 27
- I**
- Immunoassays, 152, 157, 161
  - IndelRealigner, 44
  - Indirect Serological Assay (ISA), 156
  - Induced pluripotent stem (iPS) cells, 168
  - Inflammatory bowel disease, 10
  - Ingenuity Pathway Analysis (IPA), 161
  - Insertions and deletions (INDELS), 42, 44, 45
  - International system for Human Cytogenomic nomenclature (ISCN), 64
  - InterPro, 94
  - IRESSA Follow-Up Measure (IFUM), 110
  - IRESSA Pan-Asia (IPASS), 107
  - Isoniazid, 237
- K**
- Kyoto Encyclopedia of Genes and Genomes (KEGG), 161, 234
- L**
- Large-scale association studies, 11
  - Leading pharmaceutical companies, 33
  - Ligand-based drug design (LBDD)
    - CoMFA, 195, 196
    - CoMSIA, 196
    - filtering methods, 191
    - pharmacophore (*see* Pharmacophore)
    - principle and motivation, 191
    - QSAR, 194, 195
    - 3D structure, 190
  - Ligand-based virtual screening, 191, 197, 256
  - Linezolid, 240
  - Logistic regression model, 52, 53
  - Long contiguous stretches of homozygosity (LCSH), 63
  - Long non-coding RNAs (lncRNAs), 42
  - Loss-of-function (LoF) tool, 96, 98
  - Loss of heterozygosity (LOH), 71
  - Luminex Corporation, 152, 159, 164
  - Luminex instrument, 154
  - Luminex xPONENT<sup>®</sup> multiplex assay analysis software, 159
- M**
- Macromolecular Structure Database (MSD), 141–142
  - MagPlex, 155
  - MagPlex-TAG, 155
  - MaxEntScan, 97, 98
  - Maximum entropy principle, 99
  - Medulloblastoma (MB), 73
  - Mendelian disease, 14
  - Methylation sequencing (Methyl-Seq), 42
  - Microarray, 11–13, 15, 31–32
  - Microarray technology
    - causative genes, 31
    - GWAS, 31
    - mutations, 32
    - NGS, 31
    - SNP, 31
    - WGS, 32
  - Microdevice, 133
  - Microsatellite markers, 11
  - Microsphere-based multiplex immunoassays (MBMIs), 156, 158
  - Microspheres, 153
  - Middle East Arab population, 31
  - Million Veterans Program (MVP), 35
  - Minor allele frequency (MAF), 45
  - MOE software, 193
  - Molecular docking analysis, 170, 205, 207
    - anti-TB herbal ligands *vs.* homology model, 269
    - binding site, 265
    - drug discovery and development process, 263
    - drug targets, 269
    - flexible-body/rigid-body docking approach, 263

- Molecular docking analysis (*cont.*)  
 herbal-based leads and antibiotics,  
 266–268  
 herbal-based molecules, 263  
 MD simulations, 269  
 parameters, 263  
 PncA, 266  
 receptor-ligand interactions, 269  
 softwares and tools, 263–265  
 virtual screening, 263
- Molecular docking tools, 208, 209
- Molecular dynamic (MD) simulations, 210,  
 211, 269, 270
- Molecular inversion probe (MIP) technology,  
 72
- Molecular mechanics/generalized born surface  
 area (MM/GBSA), 244
- Molecular modelling, 244, 257, 263–265
- Monogenic/single-gene disorder, 86
- Multi-drug resistance (MDR), 188
- Multidrug-resistant tuberculosis (MDR-TB),  
 234
- Multiple analyte profiling (xMAP) technology  
 dyed polypropylene/magnetic  
 microspheres, 153  
 functional bioinformatics analysis, 159, 163  
 instruments, 152  
 mechanism, signal detection, 155  
 principle of  
 bead based suspension array system,  
 153  
 biomarker studies, 154  
 magnetic beads, 155  
 MAGPIX fluorescent imager, 156  
 microspheres, 153, 154  
 solid-phase isolation method, 152
- Multiplex detection, 153, 156, 157
- Multipotent germ line stem cells (mGSSs), 168
- Mutation  
 cardiac arrhythmia panel, 32  
 Huntington disease, 27  
 Middle East Arab population, 31  
 monogenic diseases, 29  
 NGS technology, 30
- Mycobacterium tuberculosis* (Mtb)  
 ADMET, 257, 258, 263  
 CADD, 234, 240, 244, 245  
 computer-aided virtual screening, 235  
 vs. conventional treatments  
 anti-tuberculosis drugs (*see* Anti-  
 tuberculosis Drugs)  
 detailed secondary structure analysis, 247  
 vs. development, novel drugs, 234  
 drug likeliness, 257, 258, 263  
 gene interaction network analysis, 246, 247  
 vs. growth inhibitory activity, 234  
 in vitro anti-TB activity, 235  
 MD simulations, 269, 270  
 metabolic pathways, 236, 237  
 molecular docking analysis (*see* Molecular  
 docking analysis)  
 novel drug targets (*see* Novel drug targets)  
 protein structure prediction  
 Ab initio/de novo, 255, 256  
 fold recognition, 255  
 homology modelling, 248, 255  
 virtual screening, 256, 257  
 visualization, 247  
 XDR, 235, 236  
 XDR-Mtb, 234  
 XDR-TB, 234
- N**
- Nanomaterials  
 HCA and HTS, 140  
 mechanisms, 140
- National Cancer Institute (NCI), 34–35
- National Center for Biotechnology  
 Information (NCBI), 14, 142
- National genome projects  
 NGS technology, 30  
 USA, 34–35  
 UK, 35  
 UK Biobank, 35–36
- National Health Service (NHS), 16
- National Human Genome Research Institute  
 (NHGRI), 34
- National Institutes of Health (NIH), 142
- National Strategic Plan (NSP), 236
- Next-generation sequencing (NGS), 29  
 analysis workflow (*see* NGS analysis  
 workflow)  
 clinical and research applications (*see*  
 Head and neck squamous cell  
 carcinoma (HNSCC))  
 clinical interventions, 40  
 data generation, 40  
 genomic research applications, 42  
 human genome project, 40  
 platforms, 40, 41
- NGS analysis workflow  
 alignment  
 calling steps, 44  
 IndelRealigner, 44  
 read duplicates, 44  
 reference genome, 43  
 tools, 44  
 data preprocessing, 42  
 variant annotation

- ANNOVAR, 46
    - functional attributes, 45
    - programs, 45
  - variant calling, 44–45
  - variant prioritization
    - decision-making step, 46
    - filtering criteria, 46
    - VAAST2, 46
  - Non-small cell lung cancer (NSCLC), 106
    - first generation EGFR TKIs, 107, 110
    - fourth generation EGFR TKIs, 115
    - second generation EGFR TKIs, 110–112
    - third generation EGFR TKIs, 112–114
  - Non-synonymous single-nucleotide variants (nsSNVs), 95, 96
  - Novel drug targets
    - conventional approaches, 246
    - databases, 246
    - gene network analyses, 246
    - metabolic pathway analysis, 246, 248
    - pathogenesis, 247
    - survival and pathogenesis, 247, 249–254
    - target identification, 245
  - Novel natural leads, 234–236, 256, 257
  - Nuclear reprogramming, 168
  - Nucleic Acid Research* journal, 7
  - Nutrient-poor environment, 236
- O**
- Open-source tools, 43
  - Oral cancer, 125
  - Oral microbiome, 137
  - Oriented Substituent Pharmacophore  
PRopErtY space (OSPPREYS)  
approach, 194
  - Oro-dental disorders, 136
  - Oro-dental stem cells, 128
- P**
- Pantothenate, 237
  - Parkinson's disease, 169
  - Partial least squares (PLS), 196
  - Pathway Studio, Reactome, 161
  - Periodontal disease, 125
  - Periodontal ligament stem cell progenitors (PDLSCs), 130
  - Periodontitis, 130, 136
  - Perl programming language, 92
  - Pfam database, 94
  - Pharmacophore
    - fingerprinting, 193, 194
    - hydrophobic feature, 192
    - IUPAC, 191
    - target molecules, 191
    - 3D, 192, 193
    - 2D, 192
    - virtual screening processes, 192
  - Pharmacophore modeling, 170
  - Plaque, 121
  - Poisson-Boltzmann/surface area (PB/SA), 209
  - Polygenic and complex diseases, 30
  - Polygenic disease, 11
  - Polymerase chain reaction (PCR), 188
  - Polymers, 214, 215
  - PolyPhen-2, 95, 96
  - Position-specific independent count (PSIC), 95
  - Position weight matrices (PWM), 286
  - Primary ciliary dyskinesia (PCD), 30
  - Primitive neuroectodermal tumors (PNET), 73
  - Principle component analysis (PCA), 196
  - PROSITE, 94
  - Pyrazinamidase (PncA), 266
  - Pyrazinamide, 238
- Q**
- Quality checks (QC), 42
  - Quantitative structure-activity relationship (QSAR), 194, 195, 217
- R**
- Radiation hybrid mapping, 27
  - Read duplicates, 44
  - Regenerative medicine, 126
  - Regulatory elements (REs), 289
  - Restriction fragment length polymorphism (RFLP), 10, 27
  - Rheumatoid arthritis (RA)
    - applications, 157
    - autoimmune inflammatory disease, 158
    - genetic and environmental factors, 158
    - LHC6003M xMAP kit, 159
    - multiplex detection, 157
    - plasma concentrations, 160
    - pro inflammatory mediators, 158
  - Rifampicin, 238
  - RNA sequencing (RNA-Seq), 42
- S**
- Saudi Genome Project group, 33
  - Second generation EGFR TKIs
    - anilinoquinazoline core, 110
    - ATP-binding domain, 110
    - mutations, 111
    - risk for rash, 111
    - T790M, 111, 112

Sequence identity (SI), 198  
 Sequence ontology (SO), 93  
 Single gene disease, 27, 30  
 Single-molecule sequencing (SMS), 136  
 Single-nucleotide polymorphisms (SNPs), 63, 86, 87  
   cancer oncogenesis, 50  
   gene of interest, 51  
   genetic studies, 49  
   web-based VEP classification, 51  
 Sjogren's syndrome, 130  
 snpEff, 46  
 Society for Maternal-Fetal Medicine (SMFM), 69  
 Solexa method, 135  
 Solid-phase isolation method, 152  
 SOLiD™ platform, 45  
 Solvation interaction energy (SIE), 244  
 Somatic cell nuclear transfer (SCNT), 168  
 Sorting Intolerant From Tolerant (SIFT), 46, 95, 96  
 Spermatogonial stem cells (SSCs), 168  
 Streptomycin, 238  
 Structural variants (SVs), 42  
 Structure-based drug design (SBDD), 189, 190  
 Structure-based virtual screening (SBVS), 197  
 Susceptibility locus, 12, 14, 17  
 Sveinsson's chorioretinal atrophy, 14  
 Sybyl/Unity software, 193

## T

Tarceva Lung Cancer Survival Treatment (TRUST), 109  
 Teicoplanin (TEIC), 188  
 Therapeutic Target Database (TTD), 246  
 Therascreen® EGFR RGQ PCR Kit, 111  
 Third generation EGFR TKIs  
   AstraZeneca and Clovis Oncology, 114  
   Gatekeeper Pharmaceuticals, 113  
   WZ4002, 113  
 Threading, 200, 201  
 Tissue engineering, 168  
 Tooth development, 122  
 Toxicity, 216, 217  
 Transcription factor (TF), 294  
 Transcription factor binding sites (TFBSs), 285  
 Transcriptional start sites (TSSs), 284  
 TRANSFAC Professional database, 286

## U

UK Biobank, 16, 35  
 The Union Ministry of Health and Family Welfare, Government, India, 236  
 UniProt, 87, 94  
 UniProt Archive (UniParc), 93  
 UniProtKB/TrEMBL, 92

## V

VAAST2, 46  
 Vancomycin (VANC), 188  
 Variant calling  
   germline, 44  
   higher read depth, 44  
   somatic variant caller tools, 45  
 Variant Calling Format (VCF), 92, 93, 97, 101  
 Variant Effect Predictor (VEP), 46, 51  
   ConDel, 96  
   CSN, 94  
   dbNSFP, 95, 96  
   downloading full/filtered results, 101  
   ensembl genome browser, 100  
   ExAC, 97  
   InterPro, 95  
   LoFtool, 96  
   MaxEntScan, 98  
   navigation panel, 101  
   Pfam, 94  
   Pie charts display, 100  
   PolyPhen-2, 95  
   PROSITE, 94  
   SIFT, 95  
   UniParc, 93  
   UniProt, 92  
   UniProtKB/TrEMBL, 93  
   web interface  
   data input form, 97–99  
   PAK3 gene variant, 99, 100  
 Variants of uncertain clinical significance (VUSs), 69  
 Virtual screening (VS), 256, 257  
   lead discovery  
   ab initio method, 201, 202  
   active site prediction, 205  
   homology modeling, 198–200  
   HTS, 196  
   LBVS, 197  
   MD, 210, 211  
   molecular docking, 205, 207  
   protein and ligand preparation, 203, 204



- protein modeling, 197, 198
  - protein validation server, 202, 203
  - QM/MM simulations, 211–213
  - scoring methods, 208–210
  - threading, 200, 201
- W**
- Wellcome Trust and Medical Research Council, 15
  - Wellcome Trust Case Control consortium, 12
  - Whole exome sequencing (WES), 30, 86
    - analysis, 42–44
    - DNA sequencing, 42
    - heterozygous SNV detection, 44
  - Whole genome bisulfite sequencing (WGBS), 42
  - Whole genome sequencing (WGS), 42, 44, 46, 86, 87, 236
- X**
- XDR *Mycobacterium tuberculosis* (XDR-Mtb), 234
- Y**
- Yeast artificial chromosome (YAC), 28
- Z**
- Zero-mode waveguides (ZMWs), 136